Skip to main content
SpringerLink
Log in

DNA Modifications and Alzheimer’s Disease

  • Chapter
  • First Online:
Neuroepigenomics in Aging and Disease

Part of the book series: Advances in Experimental Medicine and Biology ((PMISB,volume 978))

Abstract

Alzheimer’s disease (AD) is a complex neurodegenerative disease, affecting millions of people worldwide. While a number of studies have focused on identifying genetic variants that contribute to the development and progression of late-onset AD, the majority of these only have a relatively small effect size. There are also a number of other risk factors, for example, age, gender, and other comorbidities; however, how these influence disease risk is not known. Therefore, in recent years, research has begun to investigate epigenetic mechanisms for a potential role in disease etiology. In this chapter, we discuss the current state of play for research into DNA modifications in AD, the most well studied being 5-methylcytosine (5-mC). We describe the earlier studies of candidate genes and global measures of DNA modifications in human AD samples, in addition to studies in mouse models of AD. We focus on recent epigenome-wide association studies (EWAS) in human AD, using microarray technology, examining a number of key study design issues pertinent to such studies. Finally, we discuss how new technological advances could further progress the research field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–91.

    Article  PubMed  Google Scholar 

  2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.

    Article  CAS  PubMed  Google Scholar 

  3. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.

    Article  CAS  PubMed  Google Scholar 

  4. Mortimer JA, Borenstein AR, Gosche KM, Snowdon DA. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol. 2005;18(4):218–23.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63(2):168–74.

    Article  PubMed  Google Scholar 

  6. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41(10):1094–9.

    Article  CAS  PubMed  Google Scholar 

  7. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45(12):1452–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ridge PG, Mukherjee S, Crane PK, Kauwe JS, Alzheimer’s Disease Genetics Consortium. Alzheimer’s disease: analyzing the missing heritability. PLoS One. 2013;8(11):e79771.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, et al. Common polygenic variation enhances risk prediction for Alzheimer’s disease. Brain J Neurol. 2015;138(Pt 12):3673–84.

    Article  Google Scholar 

  10. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349–56.

    Article  CAS  PubMed  Google Scholar 

  11. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–16.

    Article  CAS  PubMed  Google Scholar 

  12. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27.

    Article  CAS  PubMed  Google Scholar 

  13. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505–12.

    Article  PubMed  Google Scholar 

  14. Hall AM, Roberson ED. Mouse models of Alzheimer’s disease. Brain Res Bull. 2012;88(1):3–12.

    Article  CAS  PubMed  Google Scholar 

  15. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995;373(6514):523–7.

    Article  CAS  PubMed  Google Scholar 

  16. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99–102.

    Article  CAS  PubMed  Google Scholar 

  17. Calhoun ME, Burgermeister P, Phinney AL, Stalder M, Tolnay M, Wiederhold KH, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A. 1999;96(24):14088–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet. 2001;10(12):1317–24.

    Article  CAS  PubMed  Google Scholar 

  19. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, Shankaranarayana Rao BS, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron. 2004;42(1):23–36.

    Article  CAS  PubMed  Google Scholar 

  20. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729–33.

    Article  CAS  PubMed  Google Scholar 

  21. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409–21.

    Article  CAS  PubMed  Google Scholar 

  22. Sanchez-Mut JV, Aso E, Panayotis N, Lott I, Dierssen M, Rabano A, et al. DNA methylation map of mouse and human brain identifies target genes in Alzheimer’s disease. Brain. 2013;136(Pt 10):3018–27.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Cong L, Jia J, Qin W, Ren Y, Sun Y. Genome-wide analysis of DNA methylation in an APP/PS1 mouse model of Alzheimer’s disease. Acta Neurol Belg. 2014;114(3):195–206.

    Article  PubMed  Google Scholar 

  24. Agbemenyah HY, Agis-Balboa RC, Burkhardt S, Delalle I, Fischer A. Insulin growth factor binding protein 7 is a novel target to treat dementia. Neurobiol Dis. 2014;62:135–43.

    Article  CAS  PubMed  Google Scholar 

  25. Thompson RF, Atzmon G, Gheorghe C, Liang HQ, Lowes C, Greally JM, et al. Tissue-specific dysregulation of DNA methylation in aging. Aging Cell. 2010;9(4):506–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Heijmans BT, Mill J. Commentary: The seven plagues of epigenetic epidemiology. Int J Epidemiol. 2012;41(1):74–8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Guintivano J, Aryee MJ, Kaminsky ZA. A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. Epigenetics. 2013;8(3):290–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Burns A, Jacoby R, Luthert P, Levy R. Cause of death in Alzheimer’s disease. Age Ageing. 1990;19(5):341–4.

    Article  CAS  PubMed  Google Scholar 

  29. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27 K discovery and replication. Am J Hum Genet. 2011;88(4):450–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ruiz-Hernandez A, Kuo CC, Rentero-Garrido P, Tang WY, Redon J, Ordovas JM, et al. Environmental chemicals and DNA methylation in adults: a systematic review of the epidemiologic evidence. Clin Epigenetics. 2015;7:55.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Crider KS, Yang TP, Berry RJ, Bailey LB. Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate’s role. Adv Nutr. 2012;3(1):21–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Hannon E, Lunnon K, Schalkwyk L, Mill J. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics. 2015;10(11):1024–32.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic changes in Alzheimer’s disease: decrements in DNA methylation. Neurobiol Aging. 2010;31(12):2025–37.

    Article  CAS  PubMed  Google Scholar 

  35. Mastroeni D, McKee A, Grover A, Rogers J, Coleman PD. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer’s disease. PLoS One. 2009;4(8):e6617.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Chouliaras L, Mastroeni D, Delvaux E, Grover A, Kenis G, Hof PR, et al. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer’s disease patients. Neurobiol Aging. 2013;34(9):2091–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Lashley T, Gami P, Valizadeh N, Li A, Revesz T, Balazs R. Alterations in global DNA methylation and hydroxymethylation are not detected in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2015;41(4):497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Coppieters N, Dieriks BV, Lill C, Faull RL, Curtis MA, Dragunow M. Global changes in DNA methylation and hydroxymethylation in Alzheimer’s disease human brain. Neurobiol Aging. 2014;35(6):1334–44.

    Article  CAS  PubMed  Google Scholar 

  39. Bradley-Whitman MA, Lovell MA. Epigenetic changes in the progression of Alzheimer’s disease. Mech Ageing Dev. 2013;134(10):486–95.

    Article  CAS  PubMed  Google Scholar 

  40. Di Francesco A, Arosio B, Gussago C, Dainese E, Mari D, D'Addario C, et al. Involvement of 5-lipoxygenase in Alzheimer’s disease: a role for DNA methylation. J Alzheimers Dis. 2013;37(1):3–8.

    CAS  PubMed  Google Scholar 

  41. Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta F, Cortini F, et al. DNA methylation in repetitive elements and Alzheimer disease. Brain Behav Immun. 2011;25(6):1078–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Hernandez HG, Mahecha MF, Mejia A, Arboleda H, Forero DA. Global long interspersed nuclear element 1 DNA methylation in a Colombian sample of patients with late-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2014;29(1):50–3.

    Article  PubMed  Google Scholar 

  43. D'Addario C, Di Francesco A, Arosio B, Gussago C, Dell'Osso B, Bari M, et al. Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One. 2012;7(6):e39186.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Arosio B, Bulbarelli A, Bastias Candia S, Lonati E, Mastronardi L, Romualdi P, et al. Pin1 contribution to Alzheimer’s disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer’s disease. Neurodegener Dis. 2012;10(1–4):207–11.

    Article  CAS  PubMed  Google Scholar 

  45. Furuya TK, Silva PN, Payao SL, Bertolucci PH, Rasmussen LT, De Labio RW, et al. Analysis of SNAP25 mRNA expression and promoter DNA methylation in brain areas of Alzheimer’s disease patients. Neuroscience. 2012;220:41–6.

    Article  CAS  PubMed  Google Scholar 

  46. Furuya TK, da Silva PN, Payao SL, Rasmussen LT, de Labio RW, Bertolucci PH, et al. SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer’s disease. Neurochem Int. 2012;61(7):973–5.

    Article  CAS  PubMed  Google Scholar 

  47. Silva PN, Furuya TK, Braga IL, Rasmussen LT, Labio RW, Bertolucci PH, et al. Analysis of HSPA8 and HSPA9 mRNA expression and promoter methylation in the brain and blood of Alzheimer’s disease patients. J Alzheimers Dis. 2014;38(1):165–70.

    PubMed  Google Scholar 

  48. Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, et al. Altered CpG methylation in sporadic Alzheimer’s disease is associated with APP and MAPT dysregulation. Hum Mol Genet. 2014;23(3):648–56.

    Article  CAS  PubMed  Google Scholar 

  49. Brohede J, Rinde M, Winblad B, Graff C. A DNA methylation study of the amyloid precursor protein gene in several brain regions from patients with familial Alzheimer disease. J Neurogenet. 2010;24(4):179–81.

    Article  CAS  PubMed  Google Scholar 

  50. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS One. 2008;3(7):e2698.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol. 2009;68(8):880–91.

    Article  CAS  PubMed  Google Scholar 

  52. Silva PN, Furuya TK, Sampaio Braga I, Rasmussen LT, de Labio RW, Bertolucci PH, et al. CNP and DPYSL2 mRNA expression and promoter methylation levels in brain of Alzheimer’s disease patients. J Alzheimers Dis. 2013;33(2):349–55.

    CAS  PubMed  Google Scholar 

  53. Sontag E, Hladik C, Montgomery L, Luangpirom A, Mudrak I, Ogris E, et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol. 2004;63(10):1080–91.

    Article  CAS  PubMed  Google Scholar 

  54. Siegmund KD, Connor CM, Campan M, Long TI, Weisenberger DJ, Biniszkiewicz D, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One. 2007;2(9):e895.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Rao JS, Keleshian VL, Klein S, Rapoport SI. Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients. Transl Psychiatry. 2012;2:e132.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman AP, et al. Genome-wide DNA methylation differences between late-onset Alzheimer’s disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis. 2012;29(3):571–88.

    CAS  PubMed  Google Scholar 

  57. Sanchez-Mut JV, Aso E, Heyn H, Matsuda T, Bock C, Ferrer I, et al. Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer’s disease. Hippocampus. 2014;24(4):363–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC, Yu L, et al. Alzheimer’s disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. Nat Neurosci. 2014;17(9):1156–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Lunnon K, Smith R, Hannon E, De Jager PL, Srivastava G, Volta M, et al. Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer’s disease. Nat Neurosci. 2014;17(9):1164–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Lord J, Cruchaga C. The epigenetic landscape of Alzheimer’s disease. Nat Neurosci. 2014;17(9):1138–40.

    Article  CAS  PubMed  Google Scholar 

  61. Smith AR, Mill J, Smith RG, Lunnon K. Elucidating novel dysfunctional pathways in Alzheimer’s disease by integrating loci identified in genetic and epigenetic studies. Neuroepigenetics. 2016;6:32–50.

    Article  Google Scholar 

  62. Chibnik LB, Yu L, Eaton ML, Srivastava G, Schneider JA, Kellis M, et al. Alzheimer’s loci: epigenetic associations and interaction with genetic factors. Ann Clin Transl Neurol. 2015;2(6):636–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Smith AR, Smith RG, Condliffe D, Hannon E, Schalkwyk L, Mill J, et al. Increased DNA methylation near TREM2 is consistently seen in the superior temporal gyrus in Alzheimer’s disease brain. Neurobiol Aging. 2016;47:35–40.

    Article  CAS  PubMed  Google Scholar 

  64. Watson CT, Roussos P, Garg P, Ho DJ, Azam N, Katsel PL, et al. Genome-wide DNA methylation profiling in the superior temporal gyrus reveals epigenetic signatures associated with Alzheimer’s disease. Genome Med. 2016;8(1):5.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Song CX, Yi C, He C. Mapping recently identified nucleotide variants in the genome and transcriptome. Nat Biotechnol. 2012;30(11):1107–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol. 2011;29(1):68–72.

    Article  CAS  PubMed  Google Scholar 

  67. Nestor CE, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Dunican D, et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res. 2012;22(3):467–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Khare T, Pai S, Koncevicius K, Pal M, Kriukiene E, Liutkeviciute Z, et al. 5-hmC in the brain is abundant in synaptic genes and shows differences at the exon-intron boundary. Nat Struct Mol Biol. 2012;19(10):1037–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Condliffe D, Wong A, Troakes C, Proitsi P, Patel Y, Chouliaras L, et al. Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer’s disease brain. Neurobiol Aging. 2014;35(8):1850–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Nestor C, Ruzov A, Meehan R, Dunican D. Enzymatic approaches and bisulfite sequencing cannot distinguish between 5-methylcytosine and 5-hydroxymethylcytosine in DNA. Biotechniques. 2010;48(4):317–9.

    Article  CAS  PubMed  Google Scholar 

  71. Stewart SK, Morris TJ, Guilhamon P, Bulstrode H, Bachman M, Balasubramanian S, et al. oxBS-450 K: a method for analysing hydroxymethylation using 450 K BeadChips. Methods. 2015;72:9–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Lunnon K, Hannon E, Smith RG, Dempster E, Wong C, Burrage J, et al. Variation in 5-hydroxymethylcytosine across human cortex and cerebellum. Genome Biol. 2016;17:27.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Field SF, Beraldi D, Bachman M, Stewart SK, Beck S, Balasubramanian S. Accurate measurement of 5-methylcytosine and 5-hydroxymethylcytosine in human cerebellum DNA by oxidative bisulfite on an array (OxBS-array). PLoS One. 2015;10(2):e0118202.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Manczak M, Park BS, Jung Y, Reddy PH. Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: implications for early mitochondrial dysfunction and oxidative damage. Neruomol Med. 2004;5(2):147–62.

    Article  CAS  Google Scholar 

  75. Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, Sattlecker M, et al. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer’s disease blood. J Alzheimers Dis. 2012;30(3):685–710.

    CAS  PubMed  Google Scholar 

  76. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290(5806):457–65.

    Article  CAS  PubMed  Google Scholar 

  77. Devall M, Mill J, Lunnon K. The mitochondrial epigenome: a role in Alzheimer’s disease? Epigenomics. 2014;6(6):665–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Devall M, Roubroeks J, Mill J, Weedon M, Lunnon K. Epigenetic regulation of mitochondrial function in neurodegenerative disease: new insights from advances in genomic technologies. Neurosci Lett. 2016;625:47–55.

    Article  CAS  PubMed  Google Scholar 

  79. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Exeter Medical School, RILD, Barrack Road, Exeter, Devon, UK

    Rebecca G. Smith B.Sc., Ph.D. & Katie Lunnon B.Sc., Ph.D.

Authors
  1. Rebecca G. Smith B.Sc., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katie Lunnon B.Sc., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katie Lunnon B.Sc., Ph.D. .

Editor information

Editors and Affiliations

  1. Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), CATALONIA, Spain

    Raul Delgado-Morales

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Smith, R.G., Lunnon, K. (2017). DNA Modifications and Alzheimer’s Disease. In: Delgado-Morales, R. (eds) Neuroepigenomics in Aging and Disease. Advances in Experimental Medicine and Biology(), vol 978. Springer, Cham. https://doi.org/10.1007/978-3-319-53889-1_16

Download citation

Publish with us

Policies and ethics

Search

Navigation